Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2012 Apr;125(1):70-4.
doi: 10.1016/j.ygyno.2011.12.440. Epub 2011 Dec 22.

Longitudinal evaluation of CA-125 velocity and prediction of ovarian cancer

Jian-Lun Xu  1 , John Commins, Edward Partridge, Thomas L Riley, Philip C Prorok, Christine C Johnson, Saundra S Buys
Affiliations
Randomized Controlled Trial

Longitudinal evaluation of CA-125 velocity and prediction of ovarian cancer

Jian-Lun Xu et al. Gynecol Oncol. 2012 Apr.

Abstract

Objective: To determine whether CA-125 velocity is a statistically significant predictor of ovarian cancer and develop a classification rule to screen for ovarian cancer.

Methods: In the ovarian component of the PLCO cancer screening trial, 28,038 women aged 55-74 had at least two CA-125 screening tests. Ovarian cancer was diagnosed in 72 (0.26%) women. A multiple logistic regression model was developed to evaluate CA-125 velocity and other related covariates as predictors of ovarian cancer. Predictive accuracy was assessed by the concordance index and measures of discrimination and calibration while the fit of the model was assessed by the Hosmer and Lemeshow's goodness-of-fit χ(2)test.

Results: CA-125 velocity decreased as the number of CA-125 measurements increased but was unaffected by age at baseline screen and family history of ovarian cancer. The average velocity (19.749U/ml per month) of the cancer group was more than 500 times the average velocity (0.035U/ml per month) of the non-cancer group.

Conclusion: Among six covariates used in the model, CA-125 velocity and time intervals between baseline and second to last screening test and between last two screening tests were statistically significant predictors of ovarian cancer. The chance of having ovarian cancer increased as velocity increased, and the chance decreased when the time intervals between baseline and the second to last screening test and between last two screening tests of an individual increased.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement

The authors have no conflicts of interest to declare.

References

    1. National Institutes of Health Consensus Development Panel on Ovarian Cancer. National Institutes of Health Consessus Conference: ovarian cancer, screening, treatment and follow-up. JAMA. 1995;273:49–7. - PubMed
    1. Wilder JL, Pavlik E, Straughn JM, et al. Clinical implications of a rising serum CA-125 with the normal range in patients with epithelial ovarian cancer: a preliminary investigation. Gynecol Oncol. 2003;89:233–5. - PubMed
    1. Gadducci A, Zola P, Landoi F, Maggino T, Sartori E, Bergamino T, Cristofani R. Serum half-life of CA-125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study. Gynecol Oncol. 1995;58:42–7. - PubMed
    1. Redman CW, Blackledge GR, Kelly K, Powell J, Buxton EJ, Luesley DM. Early serum CA-125 response and outcome in epithelial ovarian cancer. Eur J Cancer. 1990;26:593–6. - PubMed
    1. Gallion HH, Hunter JE, van Nagell JR, Averette HE, Cain JM, Copeland LJ, et al. The prognostic implications of low serum CA-125 levels prior to the second-look operations for Stage III and IV epithelial ovarian cancer. Gynecol Oncol. 1992;46:29–32. - PubMed

Publication types